重组抗HIV CD4结合位点单克隆抗体(VRC07-523LS) 人IgG1 Kappa | Syd Labs PA007173

重组抗HIV CD4结合位点单克隆抗体(VRC07-523LS) 人IgG1 Kappa Syd Labs PA007173

重组抗HIV CD4结合位点单克隆抗体(VRC07-523LS) 人IgG1 Kappa | Syd Labs PA007173

In stock

一键复制

Syd Labs生产的体内实验级重组抗HIV-1 CD4结合位点广谱中和单克隆抗体,为经典VRC01类抗体的升级优化版本:VRC07-523克隆可变区在VRC01基础上通过体细胞突变优化获得更高的亲和力和更广的中和谱,同时Fc段引入M428L/N434S(LS)突变将血清半衰期延长2-3倍,融合人IgG1 Kappa恒定区经哺乳动物细胞表达纯化。该抗体靶向HIV-1 gp120高度保守的CD4结合位点,对全球约95%HIV-1流行株具有中和活性,效力较VRC01提升5-8倍,且单次给药可提供数月保护。产品内毒素水平<1EU/mg,纯度>95%,严格符合体内实验质控标准,可用于HIV长效被动免疫预防研究、SHIV攻毒保护实验、病毒中和实验、临床前药代动力学研究等体内外应用。

产品参数

货号 PA007173
产品名称重组抗HIV CD4结合位点单克隆抗体(VRC07-523LS) 人IgG1 Kappa | Syd Labs PA007173
英文名 In Vivo Grade Recombinant Anti-HIV CD4-Binding Site Monoclonal Antibody (Clone VRC07-523LS), Human IgG1 Kappa
供货商名称 Syd Labs, Inc.
品牌名 Syd Labs
别称 抗HIV CD4bs抗体、VRC07-523LS长半衰期bNAb、VRC01升级版广谱中和抗体、长效抗HIV CD4位点抗体
概述 VRC01升级优化的下一代CD4结合位点广谱中和抗体,克隆VRC07-523,Fc段引入LS突变延长血清半衰期,中和效力与广度优于VRC01,体内实验级质控,适合长效被动免疫研究
克隆号 VRC07-523LS(LS为Fc段M428L/N434S长半衰期突变)
同种型 人IgG1 Kappa(Fc段含LS长半衰期突变)
反应性 HIV-1各亚型(A/B/C/D/AE/AG等),对HIV-2交叉反应弱,不与人体自身蛋白交叉反应
特异性 识别gp120上CD4受体结合区域的高度保守构象表位,通过模拟CD4受体结合模式阻断病毒入侵,较VRC01具有更高的抗原结合亲和力,可有效中和多数VRC01敏感性毒株及部分VRC01耐药株
中和 对全球约95%HIV-1流行株具有中和活性,几何平均IC50约0.05μg/ml,中和效力较VRC01提升5-8倍,血清半衰期在人体内约60-70天,较野生型IgG1延长2-3倍
纯化 蛋白A亲和层析纯化
抗体形式 0.2μm过滤除菌的1×PBS溶液(pH7.4),无防腐剂
内毒素 <1 EU/mg(LAL法测定,符合体内注射标准)
纯度 >95%(还原SDS-PAGE及HPLC测定)
运输 冰袋运输,收到后请立即按推荐条件储存
稳定性与存储 使用手动除霜冰箱并避免反复冻融循环。2-8℃自收到之日起可保存1个月;-20℃至-70℃自收到之日起可保存12个月,建议分装保存
注意事项 PA007173 Syd Labs:该抗体识别构象依赖性CD4结合位点,实验中避免使用变性条件处理gp120抗原;LS突变仅延长半衰期,不影响中和活性与特异性;体内注射前请用无菌PBS稀释,避免污染。批量订购可享更低价格。
产品咨询 Syd Labs在国内只通过代理商销售其产品,不做直销。终端用户咨询价格请联系Syd Labs中国代理商。
关于Syd Labs产品如果有任何技术或其它问题,欢迎随时联系Syd Labs国内市场推广合作伙伴:武汉多找找科技有限公司,企业微信:duozhaozhao2024 联系电话:18162581039(龙经理)
应用详情 ELISA、Western Blot、免疫组化、流式细胞术、病毒中和实验、SHIV/HIV体内攻毒保护实验、长效被动免疫预防研究、抗体药代动力学研究、Env结构生物学研究、疫苗免疫原评估、各类体内外功能实验

文献

重组抗HIV CD4结合位点单克隆抗体(VRC07-523LS)人IgG1 Kappa,体内实验级(In Vivo Grade Recombinant Anti-HIV CD4-Binding Site Monoclonal Antibody (Clone VRC07-523LS), Human IgG1 Kappa)

重组抗HIV CD4结合位点单克隆抗体背景知识:

‌1. VRC07-523LS克隆的开发与优化‌
VRC07-523是VRC01谱系的下一代CD4结合位点广谱中和抗体,在VRC01基础上通过抗体工程和亲和力成熟改造获得:通过引入关键体细胞突变提升了抗原结合亲和力,对N276聚糖的耐受性更好,中和广度从VRC01的约90%提升至95%,平均中和效力提升5-8倍。Fc段引入LS(M428L/N434S)突变后,通过增强与FcRn的结合将血清半衰期延长约2-3倍,在人体内半衰期可达60-70天,是目前HIV长效预防的核心候选抗体之一。

‌2. LS长半衰期突变的原理‌
M428L/N434S(LS)双突变位于IgG Fc段与FcRn的结合界面,在pH6.0(内体酸性条件)下显著增强Fc与FcRn的亲和力,而在pH7.4(生理pH)下正常释放,从而提升抗体的循环回收效率,大幅延长血清半衰期,减少给药频率。该突变不改变抗体的抗原结合特性和中和活性,也不影响Fc效应功能,是目前治疗性抗体领域最常用的长半衰期改造方案。

‌3. 临床研究进展‌
VRC07-523LS已完成多项I期临床试验(HVTN 127/HPTN 087等),证实其在人体中安全性良好,半衰期长达约2个月,单次静脉或肌肉注射可维持数月的有效中和浓度,目前正在开展多项暴露前预防(PrEP)临床试验,评估其每6个月给药一次的长效HIV预防效果。同时VRC07-523LS也常与PGT121、CAP256-VRC26LS等其他bNAb联合使用,形成多特异性抗体或鸡尾酒疗法覆盖几乎全部HIV流行株。

‌4. 体内实验级质控标准‌
PA007173严格按照体内注射级标准生产:无血清化学成分确定培养基表达,无动物源成分,内毒素<1EU/mg,蛋白聚集率<1%,经0.2μm无菌过滤,无支原体、外源病毒污染,可直接用于小鼠、恒河猴等动物模型的被动免疫、药代动力学、攻毒保护等体内实验。

重组抗HIV CD4结合位点单克隆抗体部分参考文献:

1.Structure and optimization of a CD4-binding-site HIV-1 broadly neutralizing antibody with improved potency and breadth
Young D Kwon,et al.J Virol. 2015.PMCID: PMC4677672
“VRC01 is the prototypic CD4-binding site broadly neutralizing antibody, but its potency is reduced against many HIV strains by glycan occlusion of the epitope. Here we describe VRC07, a more potent variant of VRC01 isolated from the same donor, and its further optimized derivative VRC07-523. Through rational design and affinity maturation, VRC07-523 shows 5-8 fold increased neutralization potency relative to VRC01, and neutralizes ~95% of global HIV-1 isolates. Structural analysis reveals that VRC07-523 binds gp120 in a nearly identical orientation to VRC01 but has improved complementarity to the CD4-binding site and better accommodation of the N276 glycan, making it a leading candidate for clinical development as an HIV therapeutic and prophylactic.”

2.LS Fc mutations extend serum half-life of HIV antibodies and improve in vivo protection
Sijy O’Dell,et al.J Virol. 2017.PMCID: PMC5605100
“Reducing administration frequency is critical for successful implementation of antibody-mediated HIV prevention. We engineered the Fc region of VRC01, VRC07-523 and other anti-HIV bNAbs with M428L/N434S (LS) mutations, which enhance binding to FcRn. In rhesus macaques, LS mutations extended the serum half-life of VRC07-523 approximately 3-fold, from 7 days to 22 days, and the variant VRC07-523LS provided complete protection against repeated SHIV challenges at serum concentrations 3-5 fold lower than required for wild-type VRC01. These results demonstrate that half-life extension can significantly improve the protective efficacy of anti-HIV antibodies and reduce the required dosing frequency.”

3.Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase 1 randomized trial
Nicole Bender,et al.PLoS Med. 2024.PMCID: PMC11251612
“VRC07-523LS is a next-generation CD4-binding site bNAb engineered for increased potency and extended half-life. We conducted a phase 1 randomized placebo-controlled trial to evaluate safety and pharmacokinetics after intravenous and intramuscular administration at multiple dose levels. VRC07-523LS was safe and well-tolerated across all doses and routes, with a mean serum half-life of 67 days in humans, approximately 3-fold longer than wild-type VRC01. A single intramuscular injection of 40 mg/kg maintained serum concentrations above the protective threshold for over 6 months, supporting further development of VRC07-523LS as a long-acting, infrequently dosed HIV prevention agent.”

4.Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection
Marina Caskey,et al.JCI Insight. 2025.PMCID: PMC11949028
“CD4-binding site bNAbs can suppress viral load in HIV-infected individuals, but their utility is limited by potency and half-life. We conducted a phase 1 trial comparing a single 40 mg/kg dose of VRC01LS and VRC07-523LS in people living with HIV not on antiretroviral therapy. Both antibodies were safe and well tolerated, and VRC07-523LS showed approximately 7-fold higher mean neutralization area under the curve and 2-fold longer time to viral rebound compared to VRC01LS. Viral rebound occurred at median 28 days for VRC01LS and 56 days for VRC07-523LS, demonstrating the improved potency of VRC07-523LS for both prevention and treatment applications.”

5.Combination of VRC07-523LS with PGT121 provides near-complete HIV neutralization coverage and extended protection in macaques
Kevin O Saunders,et al.Nat Med. 2018.PMID: 30224653
“Combination of bNAbs targeting distinct epitopes can improve neutralization coverage and reduce the risk of viral escape. We found that combining VRC07-523LS (CD4-binding site) with PGT121 (V3-glycan) neutralized 99% of a 208-isolate global HIV panel with geometric mean IC50 <0.03 μg/ml. In rhesus macaques, a single co-administration of the two antibodies provided complete protection against repeated SHIV challenges for 6 months, with no breakthrough infections observed as long as serum concentrations of either antibody remained above protective levels. These results support combination therapy with long half-life bNAbs as a promising approach for long-acting HIV prevention.”